Biofrontera (BFRI) Common Equity (2020 - 2025)

Biofrontera's Common Equity history runs 6 years deep, the most recent figure standing at $10.5 million for Q4 2025.

• On a quarterly basis, Common Equity rose 136.41% year-over-year to $10.5 million in Q4 2025; TTM through Dec 2025 was $10.5 million, a 136.41% increase from a year earlier, with the FY2025 full-year figure at $10.5 million, up 136.41% from the prior year.
• Common Equity rose to $10.5 million in Q4 2025 per BFRI's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Common Equity topped out at $23.9 million in Q4 2022 and bottomed at -$17.4 million in Q3 2021.
• The 5-year median for Common Equity is $5.2 million (2023), against an average of $6.2 million.
• Across the five-year window, Common Equity jumped 1359.72% in 2022 and slumped 146.67% in 2025, its largest moves.
• Year by year, Common Equity stood at $11.3 million in 2021, then soared by 110.6% to $23.9 million in 2022, then plunged by 79.93% to $4.8 million in 2023, then declined by 7.51% to $4.4 million in 2024, then jumped by 136.41% to $10.5 million in 2025.
• Per Business Quant, the three latest BFRI Common Equity figures stand at $10.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$4.7 million (Q2 2025).